TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31001633
Drug: Memory probe
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memory probe vaccination (15 µg each of GI.1 and GII.4c VLPs with Al(OH)3)
Study: 9742478
Drug: Pediatric powder
Normalized name: VIVONEX PEDIATRIC POWDER,PKT,51GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric powder formulation of didanosine (ddI)
Study: 9742478
Drug: Buffered didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered didanosine (ddI) tablets
Study: 8061335
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (bismuth subcitrate 120 mgx4 + amoxycillin 500 mgx4 + metronidazole 250 mgx4)
Study: 8061335
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (amoxycillin 500 mgx4 + metronidazole 250 mgx4)
Study: 2564267
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control drug (metaproterenol or cromolyn)
Study: 4121478
Drug: Hydromorphone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (1.25 mg)
Study: 4121478
Drug: Hydromorphone (0.95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.95 mg)
Study: 9512672
Drug: Standard regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regional therapy with radiotherapy and surgery
Study: 9512672
Drug: Chemotherapy, surgery,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, surgery, and radiotherapy (previously piloted approach)
Study: 9512672
Drug: Paclitaxel, gemcitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, gemcitabine, and vinorelbine in combination with cisplatin
Study: 7844211
Drug: 16 beta‐methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 beta‐methylprednisolone (0, 16 or 60 mg/day) for 4 days from the day of oocyte retrieval
Study: 3348163
Drug: Fluoride supplementation
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride supplementation (10 or 20 mg F/d as sodium fluoride) during bed rest weeks 6-10
Study: 31037967
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance therapy after first-line chemotherapy
Study: 31037967
Drug: Placebo maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maintenance therapy after first-line chemotherapy
Study: 26518420
Drug: 3-month dual
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month dual antiplatelet therapy (DAPT) after CoCr-EES implantation
Study: 25524969
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein plus potassium bicarbonate supplement
Study: 19091800
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (1.5 g/d (n‐3) LCPUFA)
Study: 16225529
Drug: Intravesical sodium
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical sodium hyaluronate (6 weekly doses)
Study: 8131242
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (275 mg x 2 capsules, total 550 mg)
Study: 30343590
Drug: IA-PRP injections
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA-PRP injections (2 ultrasound-guided injections)
Study: 30343590
Drug: Corticosteroids (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (2 ultrasound-guided intra-articular methylprednisolone and lidocaine injections at a 2-week interval)
Study: 22018126
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg ethinyl estradiol and 3 mg drospirenone 21/7 regimen (Group 1) for 6 months
Study: 22018126
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg ethinyl estradiol and 3 mg drospirenone 24/4 regimen (Group 2) for 6 months
Study: 10714852
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol and alfentanil
Study: 8956797
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 40 mg m-2 + Etoposide (VP16) 100 mg m-2 on days 1-3 (arm A)
Study: 8956797
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 30 mg m-2 on days 2 and 3 + Carboplatin (CBDCA) 250 mg m-2 on day 1 + Etoposide (VP16) 100 mg m-2 on days 1-3 + Vinorelbine (NVB) 30 mg m-2 on day 1 (arm B)
Study: 2410317
Drug: Sucrose (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (24 +/- 13 g/day)
Study: 2410317
Drug: Sodium cyclamate
Normalized name: Sodium cyclamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cyclamate (348 +/- 270 mg/day)
Study: 29301920
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for 18 months
Study: 20688862
Drug: Volume targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume targeted ventilation at 4 ml/kg
Study: 20688862
Drug: Volume targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume targeted ventilation at 6 ml/kg
Study: 6380331
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of 400 micrograms beclomethasone dipropionate
Study: 6380331
Drug: Powder administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder administration of 400 micrograms beclomethasone dipropionate (Rotacaps)
Study: 28687982
Drug: ACB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB plus PCI (group B, ACB with 0.375% ropivacaine 30 ml + PCI with 0.2% ropivacaine 50 ml)
Study: 28687982
Drug: ACB (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB (group A, ACB with 0.375% ropivacaine 30 ml)
Study: 28687982
Drug: LIA (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA (group C, local infiltration with 0.2% ropivacaine 100 ml)
Study: 19383058
Drug: High-dose metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoprolol 190 mg
Study: 19383058
Drug: Low-dose metoprolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metoprolol 95 mg
Study: 19383058
Drug: All beta-blocker
Normalized name: all-trans-beta-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All beta-blocker treatments
Study: 11849202
Drug: Test mucoadhesive
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test mucoadhesive solution (TS)
Study: 11849202
Drug: Reference commercial
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference commercial solution (RS)
Study: 10634389
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate
Study: 10634389
Drug: Raloxifene -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene - 60 mg/day
Study: 10634389
Drug: Raloxifene -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene - 120 mg/day
Study: 9193219
Drug: Topical budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical budesonide powder (800 micrograms or 400 micrograms daily)
Study: 9193219
Drug: Surgical removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical removal or a single injection of sustained released betamethasone (for failed therapy)
Study: 9193219
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (monitoring phase after treatment)
Study: 3532680
Drug: Self-administered postoperative
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered postoperative prophylactic positive expiratory pressure (S-PEP)
Study: 23168367
Drug: R-CHOEP-14 (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOEP-14 (conventional chemotherapy with rituximab)
Study: 23168367
Drug: R-MegaCHOEP (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-MegaCHOEP (high-dose chemotherapy with rituximab)
Study: 17850608
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% benzocaine gel
Study: 10636366
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg daily for 50 days)
Study: 7751733
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Lomefloxacin (LFLX)
Study: 7751733
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Lomefloxacin (LFLX)
Study: 2143361
Drug: Loratadine (Clarityn)
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine (Clarityn) 10 mg once daily
Study: 2143361
Drug: Clemastine (Tavegyl)
Normalized name: clemastine Oral Tablet [Tavegil]
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine (Tavegyl) 1 mg twice daily
Study: 23924389
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (2000 IU daily) in DMT2 patients
Study: 23924389
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Oral agents
Study: 15500940
Drug: Fish gelatin
Normalized name: Fish Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish gelatin (3.61 g cumulative dose)
Study: 15500940
Drug: Fish gelatin
Normalized name: Fish Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish gelatin (7.61 g cumulative dose)
Study: 3292699
Drug: Live cold‐recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(7.9) EID50/ml
Study: 3292699
Drug: Live cold‐recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(7.25) EID50/ml
Study: 3292699
Drug: Live cold‐recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(5.7) EID50/ml
Study: 14578732
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ursodeoxycholic acid daily for 6 months
Study: 8970280
Drug: 20 gm
Normalized name: HYQVIA 20 GM / 200 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 gm supplement of All Bran and natural bran
Study: 1473667
Drug: Midazolam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.03 mg/kg starting dose, titrated incrementally)
Study: 1473667
Drug: Diazepam (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.10 mg/kg starting dose, titrated incrementally)
Study: 6327927
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment with reinduction chemotherapy
Study: 6327927
Drug: Three different
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three different chemotherapy regimens for remission induction
Study: 30315403
Drug: Home-based or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based or group-based exercise (twice weekly for 1 year)
Study: 22495338
Drug: Cognitive stimulation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation, physical activity, and socialization (active treatment group)
Study: 28240592
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID in LTE studies
Study: 28240592
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg BID in LTE studies
Study: 25029428
Drug: Tapering prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering prednisolone for 6 months
Study: 25029428
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for 3 months followed by matching-placebo for 3 months
Study: 21483385
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (3 mg) before incision (MO1 group)
Study: 21483385
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline before incision and morphine after wound closure (MO2 group)
Study: 19760046
Drug: Nausea and
Normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nausea and vomiting, analgesic and antiemetic requirement, level of pain, quality of life
Study: 25992639
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine
Study: 14530809
Drug: TAC (docetaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (docetaxel, doxorubicin, cyclophosphamide) 75/50/500 mg/m2 6xq3wk
Study: 14530809
Drug: FAC (5‐fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) 500/50/500 mg/m2 6x q3wk
Study: 9145856
Drug: Aminosidine sulfate
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine sulfate (12 mg/kg)
Study: 9145856
Drug: Aminosidine sulfate
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine sulfate (15 mg/kg)
Study: 8181328
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium and albuterol
Study: 3695494
Drug: Fluoxymesterone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxymesterone (5 mg p.o. b.i.d.) for 3 days before and on the day of chemotherapy
Study: 3695494
Drug: Cyclic i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic i.v. chemotherapy with cytoxan, adriamycin and 5-fluorouracil
Study: 18691861
Drug: Budesonide-containing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-containing treatment
Study: 18691861
Drug: Formoterol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol treatment
Study: 12668406
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus exposure therapy
Study: 9543786
Drug: Primary vaccination
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary vaccination (3 doses)
Study: 9543786
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination (1 dose) after vaccination 7 years earlier
Study: 9543786
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with immune status based on past infection (3 doses)
Study: 30701736
Drug: Nicorandil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (30 mg/day for 2 days and 1 day before PCI, 20 mg 2 hours before PCI, 10 mg 6 hours after PCI)
Study: 27296040
Drug: Dose-escalated concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated concurrent chemoradiotherapy (CRT) with tumor doses of 63 to 73 Gy in 30 once-daily fractions over 6 weeks with 2 concurrent cycles of cisplatin and vinorelbine.
Study: 19944650
Drug: ALO-01 (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO-01 (morphine sulfate and naltrexone hydrochloride)
Study: 19944650
Drug: Extended-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release morphine sulfate (ERMS)
Study: 16946602
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride interventions
Study: 12659989
Drug: Trimethazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethazidine (60 mg) + Diltiazem (90 mg)
Study: 11126034
Drug: meperidine (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine (0.7 mg/kg) or midazolam (0.035 mg/kg) intravenously
Study: 23541423
Drug: no medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: no medication (control group)
Study: 1388878
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU nHuIFN alpha once daily orally for 6 weeks
Study: 3902200
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to both treatments
Study: 21635992
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg, BID for 12 weeks
Study: 16117955
Drug: Lambdacyhalothrin residual
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lambdacyhalothrin residual house spraying (25 mg/m²)
Study: 9596981
Drug: Phenylalanine 1
Normalized name: phenylalanine 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylalanine 1 g/d (58 subjects)
Study: 9596981
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 g/d (38 subjects)
Study: 8257205
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power laser treatment (12 J/cm2 for 30 s, 12 treatments over four weeks)
Study: 3928053
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump
Study: 28253079
Drug: Yohimbine (α2‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (α2‐adrenoceptor antagonist)
Study: 28253079
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Yohimbine and Hydrocortisone)
Study: 25768023
Drug: Telecare intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telecare intervention (data uploaded daily to a nurse-led monitoring station)
Study: 8554251
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g of lactulose)
Study: 8554251
Drug: Both fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both fiber preparations and lactulose
Study: 1864100
Drug: Terbutaline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.5 mg) inhaled with positive expiratory pressure (PEP)
Study: 1864100
Drug: Terbutaline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.5 mg) inhaled without PEP
Study: 1864100
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray inhaled with PEP
Study: 29417384
Drug: Agave fructans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agave fructans (96 mg/bw for 12 weeks)
Study: 26997623
Drug: Protein isolates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein isolates (60 g/day)
Study: 26997623
Drug: Maltodextrin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (60 g/day)
Study: 20581351
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g/day) and Vitamin E (400 IU/day) supplementation during pregnancy
Study: 12121931
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg i.v. b.i.d. on day 1 followed by 3 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 200 mg orally b.i.d. for days 8 to 14
Study: 12121931
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg i.v. b.i.d. on day 1 followed by 5 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 400 mg orally b.i.d. for days 8 to 14
Study: 12121931
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg i.v. b.i.d. on day 1 followed by 4 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 300 mg orally b.i.d. for days 8 to 14
Study: 7861219
Drug: ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (50 mg every 6 hours)
Study: 7181805
Drug: Benactyzine hydrochloride
Normalized name: benactyzine hydrochloride
DrugBank: Benactyzine (DB09023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benactyzine hydrochloride (intramuscular administration)
Study: 31533151
Drug: Amniotic Suspension
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotic Suspension Allograft (ASA)
Study: 24463662
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D concentrations <30 nmol/L
Study: 24463662
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D concentrations 50-74 nmol/L
Study: 24463662
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D concentrations ≥75 nmol/L
Study: 24463662
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D concentrations ≥50 nmol/L in white women
Study: 24463662
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D concentrations ≥50 nmol/L in nonobese women
Study: 10893378
Drug: Atropine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.01 mg/kg body weight, IM injection)
Study: 10893378
Drug: Glycopyrrolate (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.005 mg/kg, IM injection)
Study: 10893378
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution placebo (approximately 2 mL, IM injection)
Study: 2884862
Drug: Pirmenol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol 50 or 100 mg intravenously
Study: 27831492
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of active treatment (WAT)
Study: 18499600
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 0.5 microg/kg
Study: 17646493
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 microg/kg